Researchers and commentators reported that AI models can now design complete bacteriophage genomes from scratch, enabling de novo phage generation. The development—covered by industry outlets—signals a potential acceleration in phage therapy design but also raises urgent biosecurity and governance questions about access, dual-use risk and oversight of sequence-generation tools. Stakeholders in biotech, regulators and institutional biosafety officers must weigh benefits for antimicrobial development against risks of misuse and consider access controls, provenance tracking and ethical frameworks.